Capstone Therapeutics (NASDAQ:CAPS) Announces Earnings Results, Misses Estimates By $0.02 EPS

Capstone Therapeutics (NASDAQ:CAPS) issued its quarterly earnings results on Wednesday. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02), FiscalAI reports. The company had revenue of $12.64 million during the quarter, compared to analysts’ expectations of $10.80 million. Capstone Therapeutics had a negative return on equity of 100.62% and a negative net margin of 41.26%.

Capstone Therapeutics Trading Down 14.0%

NASDAQ:CAPS opened at $0.33 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.00 and a quick ratio of 0.26. Capstone Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $2.07. The stock’s 50-day moving average is $0.51 and its two-hundred day moving average is $0.66. The stock has a market cap of $4.78 million, a PE ratio of -0.10 and a beta of -1.52.

Hedge Funds Weigh In On Capstone Therapeutics

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC bought a new stake in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned approximately 1.51% of Capstone Therapeutics at the end of the most recent reporting period. Institutional investors own 2.55% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Capstone Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.